Treatment of idiopathic pulmonary fibrosis

被引:17
作者
Daniels, Craig E. [1 ]
Ryu, Jay H. [1 ]
机构
[1] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA
关键词
bosentan; idiopathic pulmonary fibrosis; N-acetylcysteine; pirfenidone; pulmonary hypertension;
D O I
10.1055/s-2006-957338
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive lung disease in most cases, and effective treatment is still lacking. This review examines the current status of treatment options and complexities in the management of patients with IPF. Although optimal therapy for IPF has not been identified, ongoing research efforts warrant reason for optimism. Current management of IPF includes not only Judicious use of available pharmacological agents tailored to individual circumstances but also patient education through realistic assessment of prognosis, discussion of pros and cons of pharmacotherapy, early consideration of lung transplantation when applicable, treatment of complications, supportive care, and encouragement to participate in clinical trials.
引用
收藏
页码:668 / 676
页数:9
相关论文
共 82 条
[1]  
Ambrosini V, 2003, EUR RESPIR J, V22, P821, DOI 10.1183/09031936.03.00022703
[2]  
Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646
[3]  
[Anonymous], 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]
[4]   Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].
Azuma, A ;
Nukiwa, T ;
Tsuboi, E ;
Suga, M ;
Abe, S ;
Nakata, K ;
Taguchi, Y ;
Nagai, S ;
Itoh, H ;
Ohi, M ;
Sato, A ;
Kudoh, S ;
Raghu, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047
[5]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[6]   Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis - Adjunctive therapy to maintenance immunosuppression [J].
Behr, J ;
Maier, K ;
Degenkolb, B ;
Krombach, F ;
Vogelmeier, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (06) :1897-1901
[7]   Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis [J].
Bjoraker, JA ;
Ryu, JH ;
Edwin, MK ;
Myers, JL ;
Tazelaar, HD ;
Schroeder, DR ;
Offord, KP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (01) :199-203
[8]   GLUTATHIONE DEFICIENCY IN THE EPITHELIAL LINING FLUID OF THE LOWER RESPIRATORY-TRACT IN IDIOPATHIC PULMONARY FIBROSIS [J].
CANTIN, AM ;
HUBBARD, RC ;
CRYSTAL, RG .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (02) :370-372
[9]   Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis [J].
Collard, HR ;
Ryu, JH ;
Douglas, WW ;
Schwarz, MI ;
Curran-Everett, D ;
King, TE ;
Brown, KK .
CHEST, 2004, 125 (06) :2169-2174
[10]   Treatment of idiopathic pulmonary fibrosis: The rise and fall of corticosteroids [J].
Collard, HR ;
King, TE .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (04) :326-328